Emerging drug design strategies in anti-influenza drug discovery.
10.1016/j.apsb.2023.08.010
- Author:
Chuanfeng LIU
1
;
Lide HU
1
;
Guanyu DONG
1
;
Ying ZHANG
1
;
Edeildo FERREIRA DA SILVA-JÚNIOR
2
;
Xinyong LIU
1
;
Luis MENÉNDEZ-ARIAS
3
;
Peng ZHAN
1
Author Information
1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.
2. Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, Maceió 57072-970, Alagoas, Brazil.
3. Centro de Biología Molecular "Severo Ochoa" (Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid), Madrid 28049, Spain.
- Publication Type:Review
- Keywords:
Anti-drug resistance;
Broad spectrum;
Drug design strategies;
High efficiency;
Influenza virus
- From:
Acta Pharmaceutica Sinica B
2023;13(12):4715-4732
- CountryChina
- Language:English
-
Abstract:
Influenza is an acute respiratory infection caused by influenza viruses (IFV), According to the World Health Organization (WHO), seasonal IFV epidemics result in approximately 3-5 million cases of severe illness, leading to about half a million deaths worldwide, along with severe economic losses and social burdens. Unfortunately, frequent mutations in IFV lead to a certain lag in vaccine development as well as resistance to existing antiviral drugs. Therefore, it is of great importance to develop anti-IFV drugs with high efficiency against wild-type and resistant strains, needed in the fight against current and future outbreaks caused by different IFV strains. In this review, we summarize general strategies used for the discovery and development of antiviral agents targeting multiple IFV strains (including those resistant to available drugs). Structure-based drug design, mechanism-based drug design, multivalent interaction-based drug design and drug repurposing are amongst the most relevant strategies that provide a framework for the development of antiviral drugs targeting IFV.
